References
- Halaseh SA, Halaseh S, Alali Y, Ashour ME, Alharayzah MJ. A review of the etiology and epidemiology of bladder cancer: All you need to know. Cureus. 2022; Jul. doi:10.7759/cureus.27330.
- Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249.
- Vosoughi A, et al. Common germline-somatic variant interactions in advanced urothelial cancer. Nat Commun. 2020;11:6195.
- Laaksonen MA, et al. The future burden of kidney and bladder cancers preventable by behavior modification in Australia: A pooled cohort study. Int J Cancer. 2020;146:874–883.
- Cheng L, Macleannan GT, Bostwick DG. Urologic surgical pathology. 4th ed. Elsevier. 2020.
- Mossanen M, et al. Incidence of germline variants in familial bladder cancer and among patients with cancer predisposition syndromes. Clin Genitourin Cancer. 2022;20:568–574.
- Riegert-Johnson DL, et al. Cancer and Lhermitte-Duclos disease are common in Cowden syndrome patients. Hered Cancer Clin Pract. 2010;8:6.
- Babjuk M, et al. European Association of Urology guidelines on non–muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol. 2022;81:75–94.
- Jacob L, Freyn M, Kalder M, Dinas K, Kostev K. Impact of tobacco smoking on the risk of developing 25 different cancers in the UK: A retrospective study of 422,010 patients followed for up to 30 years. Oncotarget. 2018;9:17420–17429.
- Tulchiner G, et al. The “COVID-19 pandemic gap” and its influence on oncologic outcomes of bladder cancer. Cancers (Basel). 2021;13:1754.
- Túri G, Kassay J, Virág A, Dózsa C, Horváth K, Lorenzovici L. Riding the pandemic waves—Lessons to be learned from the COVID-19 crisis management in Romania. Trop Med Infect Dis. 2022;7:122.
- Travassos TC, De Oliveira JMI, Selegatto IB, Reis LO. COVID-19 impact on bladder cancer—Orientations for diagnosing, decision making, and treatment. Am J Clin Exp Urol. 2021;9:132–139.
- Campi R, et al. Assessing the burden of nondeferrable major urooncologic surgery to guide prioritisation strategies during the COVID-19 pandemic: Insights from three Italian high-volume referral centres. Eur Urol. 2020;78:11–15.
- Wallis CJD, et al. Risks from deferring treatment for genitourinary cancers: A collaborative review to aid triage and management during the COVID-19 pandemic. Eur Urol. 2020;78:29–42.
- Gravas S, et al. Prioritising urological surgery in the COVID-19 era: A global reflection on guidelines. Eur Urol Focus. 2020;6:1104–1110.
- Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249.
- Anderson S, et al. A retrospective cohort study of bladder cancer following the COVID-19 pandemic: Are patients presenting with more aggressive disease? Ann Med Surg. 2022;81:104430.
- Alexander CE, et al. Understanding the long-term impact of the COVID-19 pandemic on non-muscle-invasive bladder cancer outcomes: 12-month follow-up data from the international, prospective COVIDSurg cancer study. BJUI Compass. 2024;5:1158–1165.
- Ribal MJ, et al. European Association of Urology Guidelines Office Rapid Reaction Group: An organisation-wide collaborative effort to adapt the European Association of Urology guidelines recommendations to the coronavirus disease 2019 era. Eur Urol. 2020;78:21–28.
- Wallis CJD, et al. Risks from deferring treatment for genitourinary cancers: A collaborative review to aid triage and management during the COVID-19 pandemic. Eur Urol. 2020;78:29–42.
- Moch H. The 2016 WHO classification of tumours of the urinary system and male genital organs. 4th ed. 2016.
- Netto GJ, et al. WHO classification of tumours, 5th edition, volume 8: Urinary and male genital tumours. 5th ed. 2022.
- Brierley JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 8th ed. 2016.
- Haileamlak A. The impact of COVID-19 on health and health systems. Ethiop J Health Sci. 2021;31:1073–1074.
- Túri G, Kassay J, Virág A, Dózsa C, Horváth K, Lorenzovici L. Riding the pandemic waves—Lessons to be learned from the COVID-19 crisis management in Romania. Trop Med Infect Dis. 2022;7:122.
- Ngwa W, et al. Cancer in sub-Saharan Africa: A Lancet Oncology Commission. Lancet Oncol. 2022;23:e251–e312.
- Tulchiner G, et al. The “COVID-19 pandemic gap” and its influence on oncologic outcomes of bladder cancer. Cancers (Basel). 2021;13:1754.
- Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249.
- Ferro M, et al. The impact of SARS-CoV-2 pandemic on time to primary, secondary resection and adjuvant intravesical therapy in patients with high-risk non-muscle invasive bladder cancer: A retrospective multi-institutional cohort analysis. Cancers (Basel). 2021;13:5276.
- Gürel A, et al. Effects of the COVID-19 pandemic on bladder cancer diagnosis and treatment processes; A Turkish multicenter study. J Urol Surg. 2022;9:165–171.
- van Hoogstraten LMC, et al. The impact of the COVID-19 pandemic on bladder cancer care in the Netherlands. Bladder Cancer. 2022;8:139–154.
- Alexander CE, et al. Understanding the long-term impact of the COVID-19 pandemic on non-muscle-invasive bladder cancer outcomes: 12-month follow-up data from the international, prospective COVIDSurg cancer study. BJUI Compass. 2024;5:1158–1165.
- Schmidt AL, et al. Cancer care disparities during the COVID-19 pandemic: COVID-19 and cancer outcomes study. Cancer Cell. 2020;38:769–770.